SYN-TECH Chem. & Pharm（1777）株式概要SYN-TECH Chem.Ltd.は、台湾、アジア、ヨーロッパ、アメリカ、そして国際的に医薬品原薬（API）を製造・販売しています。 詳細1777 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績2/6財務の健全性6/6配当金5/6報酬株価収益率（ 12.4 x） TW市場（ 22.5 x）を下回っています。リスク分析利益率(20.4%)は昨年より低い(29.3%) 不安定な配当実績 すべてのリスクチェックを見る1777 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueNT$Current PriceNT$71.50218.3% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture02b2016201920222025202620282031Revenue NT$1.9bEarnings NT$388.0mAdvancedSet Fair ValueView all narrativesSYN-TECH Chem. & Pharm. Co., Ltd. 競合他社Nang Kuang PharmaceuticalSymbol: TWSE:1752Market cap: NT$3.3bSyngen BiotechLtdSymbol: TPEX:8279Market cap: NT$2.6bJohnson Chemical Pharmaceutical WorksSymbol: TPEX:4747Market cap: NT$2.6bVetnostrum Animal HealthSymbol: TWSE:6936Market cap: NT$2.4b価格と性能株価の高値、安値、推移の概要SYN-TECH Chem. & Pharm過去の株価現在の株価NT$71.5052週高値NT$91.2052週安値NT$70.00ベータ-0.0861ヶ月の変化0%3ヶ月変化n/a1年変化-20.64%3年間の変化-18.84%5年間の変化-11.73%IPOからの変化254.43%最新ニュースReported Earnings • May 11First quarter 2026 earnings released: EPS: NT$1.00 (vs NT$1.70 in 1Q 2025)First quarter 2026 results: EPS: NT$1.00 (down from NT$1.70 in 1Q 2025). Revenue: NT$275.6m (down 13% from 1Q 2025). Net income: NT$71.7m (down 5.4% from 1Q 2025). Profit margin: 26% (up from 24% in 1Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.New Risk • Mar 04New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.13b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (91% payout ratio). Profit margins are more than 30% lower than last year (20% net profit margin). Market cap is less than US$100m (NT$3.13b market cap, or US$99.1m).Reported Earnings • Feb 28Full year 2025 earnings released: EPS: NT$5.87 (vs NT$8.82 in FY 2024)Full year 2025 results: EPS: NT$5.87 (down from NT$8.82 in FY 2024). Revenue: NT$1.30b (up 3.4% from FY 2024). Net income: NT$261.6m (down 34% from FY 2024). Profit margin: 20% (down from 31% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.お知らせ • Feb 24SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, May 28, 2026SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, May 28, 2026. Location: no,168, k`ai yuan rd., sinying district, tainan city TaiwanReported Earnings • Nov 07Third quarter 2025 earnings released: EPS: NT$1.73 (vs NT$2.60 in 3Q 2024)Third quarter 2025 results: EPS: NT$1.73 (down from NT$2.60 in 3Q 2024). Revenue: NT$336.7m (up 1.9% from 3Q 2024). Net income: NT$77.4m (down 33% from 3Q 2024). Profit margin: 23% (down from 35% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 1% per year.Reported Earnings • Aug 07Second quarter 2025 earnings released: EPS: NT$0.37 (vs NT$2.21 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.37 (down from NT$2.21 in 2Q 2024). Revenue: NT$324.8m (down 5.3% from 2Q 2024). Net income: NT$16.6m (down 83% from 2Q 2024). Profit margin: 5.1% (down from 29% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 3% per year.最新情報をもっと見るRecent updatesReported Earnings • May 11First quarter 2026 earnings released: EPS: NT$1.00 (vs NT$1.70 in 1Q 2025)First quarter 2026 results: EPS: NT$1.00 (down from NT$1.70 in 1Q 2025). Revenue: NT$275.6m (down 13% from 1Q 2025). Net income: NT$71.7m (down 5.4% from 1Q 2025). Profit margin: 26% (up from 24% in 1Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.New Risk • Mar 04New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.13b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (91% payout ratio). Profit margins are more than 30% lower than last year (20% net profit margin). Market cap is less than US$100m (NT$3.13b market cap, or US$99.1m).Reported Earnings • Feb 28Full year 2025 earnings released: EPS: NT$5.87 (vs NT$8.82 in FY 2024)Full year 2025 results: EPS: NT$5.87 (down from NT$8.82 in FY 2024). Revenue: NT$1.30b (up 3.4% from FY 2024). Net income: NT$261.6m (down 34% from FY 2024). Profit margin: 20% (down from 31% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.お知らせ • Feb 24SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, May 28, 2026SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, May 28, 2026. Location: no,168, k`ai yuan rd., sinying district, tainan city TaiwanReported Earnings • Nov 07Third quarter 2025 earnings released: EPS: NT$1.73 (vs NT$2.60 in 3Q 2024)Third quarter 2025 results: EPS: NT$1.73 (down from NT$2.60 in 3Q 2024). Revenue: NT$336.7m (up 1.9% from 3Q 2024). Net income: NT$77.4m (down 33% from 3Q 2024). Profit margin: 23% (down from 35% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 1% per year.Reported Earnings • Aug 07Second quarter 2025 earnings released: EPS: NT$0.37 (vs NT$2.21 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.37 (down from NT$2.21 in 2Q 2024). Revenue: NT$324.8m (down 5.3% from 2Q 2024). Net income: NT$16.6m (down 83% from 2Q 2024). Profit margin: 5.1% (down from 29% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 3% per year.Upcoming Dividend • Jul 14Upcoming dividend of NT$5.30 per shareEligible shareholders must have bought the stock before 21 July 2025. Payment date: 15 August 2025. Payout ratio is a comfortable 62% and this is well supported by cash flows. Trailing yield: 6.3%. Within top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (2.6%).Declared Dividend • Jun 11Dividend increased to NT$5.30Dividend of NT$5.30 is 51% higher than last year. Ex-date: 21st July 2025 Payment date: 15th August 2025 Dividend yield will be 6.0%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (62% earnings payout ratio) and cash flows (49% cash payout ratio). The dividend has increased by an average of 5.9% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 9.1% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.Reported Earnings • May 09First quarter 2025 earnings released: EPS: NT$1.70 (vs NT$1.96 in 1Q 2024)First quarter 2025 results: EPS: NT$1.70 (down from NT$1.96 in 1Q 2024). Revenue: NT$315.8m (up 17% from 1Q 2024). Net income: NT$75.8m (down 13% from 1Q 2024). Profit margin: 24% (down from 32% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year and the company’s share price has also increased by 12% per year.お知らせ • Apr 30SYN-TECH Chem. & Pharm. Co., Ltd. to Report Q1, 2025 Results on May 07, 2025SYN-TECH Chem. & Pharm. Co., Ltd. announced that they will report Q1, 2025 results on May 07, 2025Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to NT$83.00, the stock trades at a trailing P/E ratio of 9.4x. Average trailing P/E is 17x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 38% over the past three years.Reported Earnings • Mar 09Full year 2024 earnings released: EPS: NT$8.82 (vs NT$5.63 in FY 2023)Full year 2024 results: EPS: NT$8.82 (up from NT$5.63 in FY 2023). Revenue: NT$1.26b (up 13% from FY 2023). Net income: NT$393.3m (up 57% from FY 2023). Profit margin: 31% (up from 23% in FY 2023). Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 16% per year.お知らせ • Feb 25SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, May 29, 2025SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, May 29, 2025. Location: no,168, k`ai yuan rd., sinying district, tainan city Taiwanお知らせ • Feb 15SYN-TECH Chem. & Pharm. Co., Ltd. to Report Fiscal Year 2024 Results on Feb 24, 2025SYN-TECH Chem. & Pharm. Co., Ltd. announced that they will report fiscal year 2024 results on Feb 24, 2025New Risk • Nov 29New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 20% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.Reported Earnings • Nov 18Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: NT$330.6m (flat on 3Q 2023). Net income: NT$116.0m (up 26% from 3Q 2023). Profit margin: 35% (up from 28% in 3Q 2023).お知らせ • Oct 26SYN-TECH Chem. & Pharm. Co., Ltd. to Report Q3, 2024 Results on Nov 04, 2024SYN-TECH Chem. & Pharm. Co., Ltd. announced that they will report Q3, 2024 results on Nov 04, 2024Reported Earnings • Aug 13Second quarter 2024 earnings released: EPS: NT$2.21 (vs NT$1.52 in 2Q 2023)Second quarter 2024 results: EPS: NT$2.21 (up from NT$1.52 in 2Q 2023). Revenue: NT$343.0m (up 40% from 2Q 2023). Net income: NT$98.6m (up 46% from 2Q 2023). Profit margin: 29% (up from 28% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 10% per year.お知らせ • Jul 27SYN-TECH Chem. & Pharm. Co., Ltd. to Report Q2, 2024 Results on Aug 05, 2024SYN-TECH Chem. & Pharm. Co., Ltd. announced that they will report Q2, 2024 results on Aug 05, 2024Upcoming Dividend • Jul 12Upcoming dividend of NT$3.50 per shareEligible shareholders must have bought the stock before 19 July 2024. Payment date: 16 August 2024. Payout ratio is a comfortable 57% but the company is not cash flow positive. Trailing yield: 3.3%. Lower than top quartile of Taiwanese dividend payers (4.2%). Higher than average of industry peers (2.0%).Buy Or Sell Opportunity • Jul 08Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 18% to NT$98.20. The fair value is estimated to be NT$79.84, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.4% over the last 3 years. Earnings per share has grown by 3.9%.Declared Dividend • Jun 22Dividend increased to NT$3.50Dividend of NT$3.50 is 17% higher than last year. Ex-date: 19th July 2024 Payment date: 16th August 2024 Dividend yield will be 3.9%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (57% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 4.1% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 1.8% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.Reported Earnings • May 19First quarter 2024 earnings released: EPS: NT$1.96 (vs NT$1.47 in 1Q 2023)First quarter 2024 results: EPS: NT$1.96 (up from NT$1.47 in 1Q 2023). Revenue: NT$269.8m (flat on 1Q 2023). Net income: NT$87.4m (up 33% from 1Q 2023). Profit margin: 32% (up from 25% in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has increased by 2% per year.お知らせ • Apr 28SYN-TECH Chem. & Pharm. Co., Ltd. to Report Q1, 2024 Results on May 06, 2024SYN-TECH Chem. & Pharm. Co., Ltd. announced that they will report Q1, 2024 results on May 06, 2024Buy Or Sell Opportunity • Apr 23Now 20% overvaluedOver the last 90 days, the stock has fallen 2.5% to NT$82.30. The fair value is estimated to be NT$68.43, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.3% over the last 3 years. Earnings per share has grown by 2.5%.Buy Or Sell Opportunity • Mar 01Now 20% overvaluedOver the last 90 days, the stock has fallen 5.5% to NT$82.40. The fair value is estimated to be NT$68.43, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 2.7%.お知らせ • Feb 27SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, Jun 20, 2024SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, Jun 20, 2024. Location: No.168, Kai Yuan Rd., Hsin-Ying District Tainan City Taiwan Agenda: To consider 2023 Business Report; to consider 2023 Audit Committee's Review Report; to consider 2023 Employees and Directors' Compensation Information; to consider Status of 2023 Cash Dividend Distribution; to consider 2023 Directors' Remuneration Information; to consider 2023 Business Report and Financial Statements; to consider distribution plan of 2023 earnings; and to consider other matters.Reported Earnings • Nov 08Third quarter 2023 earnings: EPS and revenues exceed analyst expectationsThird quarter 2023 results: EPS: NT$2.07 (down from NT$2.54 in 3Q 2022). Revenue: NT$330.4m (up 17% from 3Q 2022). Net income: NT$92.5m (down 18% from 3Q 2022). Profit margin: 28% (down from 40% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates by 29%. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 4% per year.Reported Earnings • Aug 08Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2023 results: EPS: NT$1.51 (down from NT$3.11 in 2Q 2022). Revenue: NT$245.1m (down 17% from 2Q 2022). Net income: NT$67.5m (down 46% from 2Q 2022). Profit margin: 28% (down from 42% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue missed analyst estimates by 3.9%. Earnings per share (EPS) exceeded analyst estimates by 18%. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 1% per year.Upcoming Dividend • Jul 14Upcoming dividend of NT$3.00 per share at 3.5% yieldEligible shareholders must have bought the stock before 21 July 2023. Payment date: 18 August 2023. Payout ratio is a comfortable 44% but the company is not cash flow positive. Trailing yield: 3.5%. Lower than top quartile of Taiwanese dividend payers (5.5%). Higher than average of industry peers (1.7%).Reported Earnings • Mar 24Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: EPS: NT$6.62 (up from NT$3.38 in FY 2021). Revenue: NT$986.3m (up 32% from FY 2021). Net income: NT$295.3m (up 184% from FY 2021). Profit margin: 30% (up from 14% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 3.7%. Earnings per share (EPS) missed analyst estimates by 4.9%. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.お知らせ • Dec 30SYN-TECH Chem. & Pharm. Co., Ltd. Announces Appointment of Corporate Governance OfficerSYN-TECH Chem. & Pharm. Co., Ltd. announced appointment of Corporate Governance Officer. Name, title, and resume of the previous position holder: N/A. Name, title, and resume of the new position holder: Maggie Juang /financial & accounting officer of Syn-Tech. Effective date: December 29, 2022.Price Target Changed • Nov 16Price target decreased to NT$80.00Down from NT$100.00, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of NT$76.40. Stock is up 9.1% over the past year. The company is forecast to post earnings per share of NT$3.02 for next year compared to NT$3.38 last year.Reported Earnings • Nov 06Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: EPS: NT$2.54 (up from NT$0.94 in 3Q 2021). Revenue: NT$281.8m (up 77% from 3Q 2021). Net income: NT$113.3m (up 302% from 3Q 2021). Profit margin: 40% (up from 18% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 37%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 07Second quarter 2022 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2022 results: EPS: NT$1.72 (up from NT$0.74 in 2Q 2021). Revenue: NT$209.1m (down 3.3% from 2Q 2021). Net income: NT$68.8m (up 209% from 2Q 2021). Profit margin: 33% (up from 10% in 2Q 2021). The increase in margin was driven by lower expenses. Revenue exceeded analyst estimates by 5.6%. Earnings per share (EPS) also surpassed analyst estimates by 192%. Over the next year, revenue is forecast to grow 32%, compared to a 39% growth forecast for the industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.お知らせ • Aug 03SYN-TECH Chem. & Pharm. Co., Ltd. Announces Executive ChangesSYN-TECH Chem. & Pharm. Co., Ltd. announced that Chun-Cheng, Hung/synthesis department manager of SCP, has replaced Chun-Tzer, Tsai/director of Syn-Tech, as Research and development officer. Syn-Tech has announced the change of research and development officer on July 1, 2022. The case was approved by the board of Syn-Tech on August 1, 2022.Upcoming Dividend • Jul 14Upcoming dividend of NT$1.93 per shareEligible shareholders must have bought the stock before 21 July 2022. Payment date: 19 August 2022. Payout ratio is a comfortable 75% but the company is paying out more than the cash it is generating. Trailing yield: 3.0%. Lower than top quartile of Taiwanese dividend payers (6.8%). In line with average of industry peers (2.8%).お知らせ • Jul 03SYN-TECH Chem. & Pharm. Co., Ltd. Announces Change of Research and Development OfficerSYN-TECH Chem. & Pharm. Co., Ltd. announced change of research and development officer. Name, title, and resume of the previous position holder: Chun-Tzer, Tsai/director of Syn-Tech. Name, title, and resume of the new position holder: Chun-Cheng, Hung/synthesis department manager of SCP. Effective date is July 1, 2022.お知らせ • Jun 22SYN-TECH Chem. & Pharm. Co., Ltd. Announces Cash Dividend, Payable on August 19, 2022SYN-TECH Chem. & Pharm. Co., Ltd. announced cash dividend of TWD 86,128,033 (TWD 2.15 per share). Ex-rights (Ex-dividend) date is July 21, 2022. Ex-rights (Ex-dividend) record date is July 27, 2022. Payment date of cash dividend distribution is August 19, 2022.Reported Earnings • May 10First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: EPS: NT$0.85 (down from NT$1.73 in 1Q 2021). Revenue: NT$159.5m (down 32% from 1Q 2021). Net income: NT$34.2m (down 34% from 1Q 2021). Profit margin: 22% (in line with 1Q 2021). Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) also surpassed analyst estimates by 73%. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.Price Target Changed • Apr 27Price target decreased to NT$66.00Down from NT$100.00, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of NT$65.30. Stock is down 35% over the past year. The company is forecast to post earnings per share of NT$2.47 for next year compared to NT$3.38 last year.Reported Earnings • Mar 12Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: EPS: NT$3.38 (down from NT$6.21 in FY 2020). Revenue: NT$746.6m (down 24% from FY 2020). Net income: NT$103.8m (down 44% from FY 2020). Profit margin: 14% (down from 19% in FY 2020). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 19%. Over the next year, revenue is expected to shrink by 9.3% compared to a 20% growth forecast for the pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 5% per year.Reported Earnings • Nov 10Third quarter 2021 earnings released: EPS NT$0.94 (vs NT$1.14 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and revenues, although profit margins were improved. Third quarter 2021 results: Revenue: NT$159.2m (down 28% from 3Q 2020). Net income: NT$28.2m (down 18% from 3Q 2020). Profit margin: 18% (up from 16% in 3Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Upcoming Dividend • Sep 09Upcoming dividend of NT$4.00 per shareEligible shareholders must have bought the stock before 16 September 2021. Payment date: 07 October 2021. Trailing yield: 5.5%. Within top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (2.3%).Reported Earnings • Aug 06Second quarter 2021 earnings released: EPS NT$0.74 (vs NT$2.35 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: NT$216.3m (down 29% from 2Q 2020). Net income: NT$22.2m (down 69% from 2Q 2020). Profit margin: 10% (down from 23% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.Reported Earnings • May 06First quarter 2021 earnings released: EPS NT$1.73 (vs NT$1.56 in 1Q 2020)The company reported a solid first quarter result with improved earnings and profit margins, although revenues were flat. First quarter 2021 results: Revenue: NT$235.6m (flat on 1Q 2020). Net income: NT$52.0m (up 11% from 1Q 2020). Profit margin: 22% (up from 20% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Apr 25Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to NT$95.60, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 17x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 35% over the past three years.分析記事 • Mar 19SYN-TECH Chem. & Pharm (GTSM:1777) Could Easily Take On More DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Mar 18SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777) agreed to acquire API synthesis department of Standard Chemical from Standard Chem & Pharm CO., LTD. (TSEC:1720) for TWD 341 million.SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777) agreed to acquire API synthesis department of Standard Chemical from Standard Chem & Pharm CO., LTD. (TSEC:1720) for TWD 341 million on March 16, 2021. The transaction will be settled by exchange of 4.5 million shares of SYN-TECH of NTD 75.24 per share. If there is insufficient exchange for one share, SYN-TECH shall, within 30 days after completing amendment registration, pay the difference between assessed business value and the share value in cash to SCP at once. The deal is subject to Standard Chemical obtaining approval from shareholders and is expected to close on October 1, 2021.Reported Earnings • Mar 18Full year 2020 earnings released: EPS NT$6.21 (vs NT$5.31 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$983.8m (up 3.9% from FY 2019). Net income: NT$186.7m (up 17% from FY 2019). Profit margin: 19% (up from 17% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 17SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, Jun 18, 2021SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, Jun 18, 2021, at 14:00 Taipei Standard Time. Location: No.168, Kai Yuan Rd., Hsin-Ying District, Tainan City Taiwan Agenda: To consider 2020 Business Report; to consider Supervisors' Review Report on 2020 Financial Statements; to consider 2020 Employees' Compensation and Directors & Supervisors' Compensation Information; to consider Syn-Tech will transfer the API synthesis department that spinning-off from S.C.P, and issue new shares; to consider 2020 Business Report and Financial Statements; to consider the proposed distribution plan for year 2020 earnings; to consider the amendment to the Articles of Incorporation; to consider the amendment to the Procedures for Election of Directors and Supervisors; to consider the amendment to the Regulations Governing the Acquisition and Disposal of Assets; to consider the amendment to the Regulations Governing Loaning of Funds; and to consider other matters.Is New 90 Day High Low • Feb 27New 90-day high: NT$82.50The company is up 9.0% from its price of NT$75.70 on 27 November 2020. The Taiwanese market is up 15% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 5.0% over the same period.分析記事 • Feb 26Here's What You Should Know About SYN-TECH Chem. & Pharm. Co., Ltd.'s (GTSM:1777) 4.6% Dividend YieldIs SYN-TECH Chem. & Pharm. Co., Ltd. ( GTSM:1777 ) a good dividend stock? How can we tell? Dividend paying companies...分析記事 • Feb 05Declining Stock and Decent Financials: Is The Market Wrong About SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777)?SYN-TECH Chem. & Pharm (GTSM:1777) has had a rough month with its share price down 1.2%. However, stock prices are...分析記事 • Jan 10SYN-TECH Chem. & Pharm's (GTSM:1777) Shareholders Are Down 11% On Their SharesIdeally, your overall portfolio should beat the market average. But every investor is virtually certain to have both...Is New 90 Day High Low • Dec 21New 90-day high: NT$77.30The company is up 2.0% from its price of NT$75.50 on 23 September 2020. The Taiwanese market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 13% over the same period.分析記事 • Dec 19SYN-TECH Chem. & Pharm (GTSM:1777) Seems To Use Debt Rather SparinglySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Nov 28Here's What You Should Know About SYN-TECH Chem. & Pharm. Co., Ltd.'s (GTSM:1777) 4.6% Dividend YieldIs SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777) a good dividend stock? How can we tell? Dividend paying companies...Reported Earnings • Nov 05Third quarter 2020 earnings released: EPS NT$1.14The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$220.3m (down 20% from 3Q 2019). Net income: NT$34.3m (down 39% from 3Q 2019). Profit margin: 16% (down from 21% in 3Q 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Oct 13New 90-day low: NT$73.70The company is down 16% from its price of NT$88.00 on 15 July 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 11% over the same period.Is New 90 Day High Low • Sep 22New 90-day low: NT$75.60The company is down 16% from its price of NT$89.50 on 24 June 2020. The Taiwanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period.株主還元1777TW PharmaceuticalsTW 市場7D1.1%3.7%2.6%1Y-20.6%-5.2%94.7%株主還元を見る業界別リターン: 1777過去 1 年間で-5.2 % の収益を上げたTW Pharmaceuticals業界を下回りました。リターン対市場: 1777は、過去 1 年間で94.7 % のリターンを上げたTW市場を下回りました。価格変動Is 1777's price volatile compared to industry and market?1777 volatility1777 Average Weekly Movement1.9%Pharmaceuticals Industry Average Movement5.6%Market Average Movement6.2%10% most volatile stocks in TW Market12.2%10% least volatile stocks in TW Market2.5%安定した株価: 1777 、 TW市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 1777の 週次ボラティリティ ( 2% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1982223n/awww.syn-tech.com.twSYN-TECH Chem Ltd.は、台湾、アジア、欧州、米州および国際的に医薬品原薬（API）を製造・販売している。同社は、抗凝固剤、注意欠陥多動性障害、骨格筋弛緩剤、鎮咳剤、鎮痒剤、かさぶた剤、抗炎症剤、解熱剤、鎮痛剤、筋弛緩剤、抗不安剤、制吐剤、抗けいれん剤、抗潰瘍剤、降圧剤、a-ブロッカー、血管拡張剤、気管支拡張剤など、様々なカテゴリーの製品を提供している、抗不安薬、精神安定薬、局所麻酔薬、鬱血除去薬、鎮痙薬、神経保護薬、抗偏頭痛薬、薬剤補助/潤滑薬、抗緑内障薬、低ナトリウム血症薬、抗うつ薬、鎮静薬、鎮痛薬、また副甲状腺機能亢進症や頻尿の治療薬、前立腺肥大症、ヘルペスウイルスのヘリカーゼ・プライマーゼ阻害薬。SYN-TECH Chem Ltd.は1982年に設立され、台湾の台南市に本社を置いている。もっと見るSYN-TECH Chem. & Pharm. Co., Ltd. 基礎のまとめSYN-TECH Chem. & Pharm の収益と売上を時価総額と比較するとどうか。1777 基礎統計学時価総額NT$3.19b収益（TTM）NT$257.51m売上高(TTM)NT$1.26b12.4xPER（株価収益率2.5xP/Sレシオ1777 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計1777 損益計算書（TTM）収益NT$1.26b売上原価NT$814.91m売上総利益NT$445.15mその他の費用NT$187.65m収益NT$257.51m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）5.77グロス・マージン35.33%純利益率20.44%有利子負債／自己資本比率5.2%1777 の長期的なパフォーマンスは？過去の実績と比較を見る配当金5.6%現在の配当利回り68%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 15:07終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋SYN-TECH Chem. & Pharm. Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Yenya KuoCapital Securities CorporationXiaowei HuangMasterlink Securities Investment Advisory
Reported Earnings • May 11First quarter 2026 earnings released: EPS: NT$1.00 (vs NT$1.70 in 1Q 2025)First quarter 2026 results: EPS: NT$1.00 (down from NT$1.70 in 1Q 2025). Revenue: NT$275.6m (down 13% from 1Q 2025). Net income: NT$71.7m (down 5.4% from 1Q 2025). Profit margin: 26% (up from 24% in 1Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
New Risk • Mar 04New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.13b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (91% payout ratio). Profit margins are more than 30% lower than last year (20% net profit margin). Market cap is less than US$100m (NT$3.13b market cap, or US$99.1m).
Reported Earnings • Feb 28Full year 2025 earnings released: EPS: NT$5.87 (vs NT$8.82 in FY 2024)Full year 2025 results: EPS: NT$5.87 (down from NT$8.82 in FY 2024). Revenue: NT$1.30b (up 3.4% from FY 2024). Net income: NT$261.6m (down 34% from FY 2024). Profit margin: 20% (down from 31% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
お知らせ • Feb 24SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, May 28, 2026SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, May 28, 2026. Location: no,168, k`ai yuan rd., sinying district, tainan city Taiwan
Reported Earnings • Nov 07Third quarter 2025 earnings released: EPS: NT$1.73 (vs NT$2.60 in 3Q 2024)Third quarter 2025 results: EPS: NT$1.73 (down from NT$2.60 in 3Q 2024). Revenue: NT$336.7m (up 1.9% from 3Q 2024). Net income: NT$77.4m (down 33% from 3Q 2024). Profit margin: 23% (down from 35% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 1% per year.
Reported Earnings • Aug 07Second quarter 2025 earnings released: EPS: NT$0.37 (vs NT$2.21 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.37 (down from NT$2.21 in 2Q 2024). Revenue: NT$324.8m (down 5.3% from 2Q 2024). Net income: NT$16.6m (down 83% from 2Q 2024). Profit margin: 5.1% (down from 29% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 3% per year.
Reported Earnings • May 11First quarter 2026 earnings released: EPS: NT$1.00 (vs NT$1.70 in 1Q 2025)First quarter 2026 results: EPS: NT$1.00 (down from NT$1.70 in 1Q 2025). Revenue: NT$275.6m (down 13% from 1Q 2025). Net income: NT$71.7m (down 5.4% from 1Q 2025). Profit margin: 26% (up from 24% in 1Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
New Risk • Mar 04New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.13b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (91% payout ratio). Profit margins are more than 30% lower than last year (20% net profit margin). Market cap is less than US$100m (NT$3.13b market cap, or US$99.1m).
Reported Earnings • Feb 28Full year 2025 earnings released: EPS: NT$5.87 (vs NT$8.82 in FY 2024)Full year 2025 results: EPS: NT$5.87 (down from NT$8.82 in FY 2024). Revenue: NT$1.30b (up 3.4% from FY 2024). Net income: NT$261.6m (down 34% from FY 2024). Profit margin: 20% (down from 31% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
お知らせ • Feb 24SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, May 28, 2026SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, May 28, 2026. Location: no,168, k`ai yuan rd., sinying district, tainan city Taiwan
Reported Earnings • Nov 07Third quarter 2025 earnings released: EPS: NT$1.73 (vs NT$2.60 in 3Q 2024)Third quarter 2025 results: EPS: NT$1.73 (down from NT$2.60 in 3Q 2024). Revenue: NT$336.7m (up 1.9% from 3Q 2024). Net income: NT$77.4m (down 33% from 3Q 2024). Profit margin: 23% (down from 35% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 1% per year.
Reported Earnings • Aug 07Second quarter 2025 earnings released: EPS: NT$0.37 (vs NT$2.21 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.37 (down from NT$2.21 in 2Q 2024). Revenue: NT$324.8m (down 5.3% from 2Q 2024). Net income: NT$16.6m (down 83% from 2Q 2024). Profit margin: 5.1% (down from 29% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 3% per year.
Upcoming Dividend • Jul 14Upcoming dividend of NT$5.30 per shareEligible shareholders must have bought the stock before 21 July 2025. Payment date: 15 August 2025. Payout ratio is a comfortable 62% and this is well supported by cash flows. Trailing yield: 6.3%. Within top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (2.6%).
Declared Dividend • Jun 11Dividend increased to NT$5.30Dividend of NT$5.30 is 51% higher than last year. Ex-date: 21st July 2025 Payment date: 15th August 2025 Dividend yield will be 6.0%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (62% earnings payout ratio) and cash flows (49% cash payout ratio). The dividend has increased by an average of 5.9% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 9.1% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Reported Earnings • May 09First quarter 2025 earnings released: EPS: NT$1.70 (vs NT$1.96 in 1Q 2024)First quarter 2025 results: EPS: NT$1.70 (down from NT$1.96 in 1Q 2024). Revenue: NT$315.8m (up 17% from 1Q 2024). Net income: NT$75.8m (down 13% from 1Q 2024). Profit margin: 24% (down from 32% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year and the company’s share price has also increased by 12% per year.
お知らせ • Apr 30SYN-TECH Chem. & Pharm. Co., Ltd. to Report Q1, 2025 Results on May 07, 2025SYN-TECH Chem. & Pharm. Co., Ltd. announced that they will report Q1, 2025 results on May 07, 2025
Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to NT$83.00, the stock trades at a trailing P/E ratio of 9.4x. Average trailing P/E is 17x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 38% over the past three years.
Reported Earnings • Mar 09Full year 2024 earnings released: EPS: NT$8.82 (vs NT$5.63 in FY 2023)Full year 2024 results: EPS: NT$8.82 (up from NT$5.63 in FY 2023). Revenue: NT$1.26b (up 13% from FY 2023). Net income: NT$393.3m (up 57% from FY 2023). Profit margin: 31% (up from 23% in FY 2023). Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 16% per year.
お知らせ • Feb 25SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, May 29, 2025SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, May 29, 2025. Location: no,168, k`ai yuan rd., sinying district, tainan city Taiwan
お知らせ • Feb 15SYN-TECH Chem. & Pharm. Co., Ltd. to Report Fiscal Year 2024 Results on Feb 24, 2025SYN-TECH Chem. & Pharm. Co., Ltd. announced that they will report fiscal year 2024 results on Feb 24, 2025
New Risk • Nov 29New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 20% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.
Reported Earnings • Nov 18Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: NT$330.6m (flat on 3Q 2023). Net income: NT$116.0m (up 26% from 3Q 2023). Profit margin: 35% (up from 28% in 3Q 2023).
お知らせ • Oct 26SYN-TECH Chem. & Pharm. Co., Ltd. to Report Q3, 2024 Results on Nov 04, 2024SYN-TECH Chem. & Pharm. Co., Ltd. announced that they will report Q3, 2024 results on Nov 04, 2024
Reported Earnings • Aug 13Second quarter 2024 earnings released: EPS: NT$2.21 (vs NT$1.52 in 2Q 2023)Second quarter 2024 results: EPS: NT$2.21 (up from NT$1.52 in 2Q 2023). Revenue: NT$343.0m (up 40% from 2Q 2023). Net income: NT$98.6m (up 46% from 2Q 2023). Profit margin: 29% (up from 28% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 10% per year.
お知らせ • Jul 27SYN-TECH Chem. & Pharm. Co., Ltd. to Report Q2, 2024 Results on Aug 05, 2024SYN-TECH Chem. & Pharm. Co., Ltd. announced that they will report Q2, 2024 results on Aug 05, 2024
Upcoming Dividend • Jul 12Upcoming dividend of NT$3.50 per shareEligible shareholders must have bought the stock before 19 July 2024. Payment date: 16 August 2024. Payout ratio is a comfortable 57% but the company is not cash flow positive. Trailing yield: 3.3%. Lower than top quartile of Taiwanese dividend payers (4.2%). Higher than average of industry peers (2.0%).
Buy Or Sell Opportunity • Jul 08Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 18% to NT$98.20. The fair value is estimated to be NT$79.84, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.4% over the last 3 years. Earnings per share has grown by 3.9%.
Declared Dividend • Jun 22Dividend increased to NT$3.50Dividend of NT$3.50 is 17% higher than last year. Ex-date: 19th July 2024 Payment date: 16th August 2024 Dividend yield will be 3.9%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (57% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 4.1% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 1.8% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Reported Earnings • May 19First quarter 2024 earnings released: EPS: NT$1.96 (vs NT$1.47 in 1Q 2023)First quarter 2024 results: EPS: NT$1.96 (up from NT$1.47 in 1Q 2023). Revenue: NT$269.8m (flat on 1Q 2023). Net income: NT$87.4m (up 33% from 1Q 2023). Profit margin: 32% (up from 25% in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has increased by 2% per year.
お知らせ • Apr 28SYN-TECH Chem. & Pharm. Co., Ltd. to Report Q1, 2024 Results on May 06, 2024SYN-TECH Chem. & Pharm. Co., Ltd. announced that they will report Q1, 2024 results on May 06, 2024
Buy Or Sell Opportunity • Apr 23Now 20% overvaluedOver the last 90 days, the stock has fallen 2.5% to NT$82.30. The fair value is estimated to be NT$68.43, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.3% over the last 3 years. Earnings per share has grown by 2.5%.
Buy Or Sell Opportunity • Mar 01Now 20% overvaluedOver the last 90 days, the stock has fallen 5.5% to NT$82.40. The fair value is estimated to be NT$68.43, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 2.7%.
お知らせ • Feb 27SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, Jun 20, 2024SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, Jun 20, 2024. Location: No.168, Kai Yuan Rd., Hsin-Ying District Tainan City Taiwan Agenda: To consider 2023 Business Report; to consider 2023 Audit Committee's Review Report; to consider 2023 Employees and Directors' Compensation Information; to consider Status of 2023 Cash Dividend Distribution; to consider 2023 Directors' Remuneration Information; to consider 2023 Business Report and Financial Statements; to consider distribution plan of 2023 earnings; and to consider other matters.
Reported Earnings • Nov 08Third quarter 2023 earnings: EPS and revenues exceed analyst expectationsThird quarter 2023 results: EPS: NT$2.07 (down from NT$2.54 in 3Q 2022). Revenue: NT$330.4m (up 17% from 3Q 2022). Net income: NT$92.5m (down 18% from 3Q 2022). Profit margin: 28% (down from 40% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates by 29%. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 4% per year.
Reported Earnings • Aug 08Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2023 results: EPS: NT$1.51 (down from NT$3.11 in 2Q 2022). Revenue: NT$245.1m (down 17% from 2Q 2022). Net income: NT$67.5m (down 46% from 2Q 2022). Profit margin: 28% (down from 42% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue missed analyst estimates by 3.9%. Earnings per share (EPS) exceeded analyst estimates by 18%. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 1% per year.
Upcoming Dividend • Jul 14Upcoming dividend of NT$3.00 per share at 3.5% yieldEligible shareholders must have bought the stock before 21 July 2023. Payment date: 18 August 2023. Payout ratio is a comfortable 44% but the company is not cash flow positive. Trailing yield: 3.5%. Lower than top quartile of Taiwanese dividend payers (5.5%). Higher than average of industry peers (1.7%).
Reported Earnings • Mar 24Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: EPS: NT$6.62 (up from NT$3.38 in FY 2021). Revenue: NT$986.3m (up 32% from FY 2021). Net income: NT$295.3m (up 184% from FY 2021). Profit margin: 30% (up from 14% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 3.7%. Earnings per share (EPS) missed analyst estimates by 4.9%. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
お知らせ • Dec 30SYN-TECH Chem. & Pharm. Co., Ltd. Announces Appointment of Corporate Governance OfficerSYN-TECH Chem. & Pharm. Co., Ltd. announced appointment of Corporate Governance Officer. Name, title, and resume of the previous position holder: N/A. Name, title, and resume of the new position holder: Maggie Juang /financial & accounting officer of Syn-Tech. Effective date: December 29, 2022.
Price Target Changed • Nov 16Price target decreased to NT$80.00Down from NT$100.00, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of NT$76.40. Stock is up 9.1% over the past year. The company is forecast to post earnings per share of NT$3.02 for next year compared to NT$3.38 last year.
Reported Earnings • Nov 06Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: EPS: NT$2.54 (up from NT$0.94 in 3Q 2021). Revenue: NT$281.8m (up 77% from 3Q 2021). Net income: NT$113.3m (up 302% from 3Q 2021). Profit margin: 40% (up from 18% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 37%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 07Second quarter 2022 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2022 results: EPS: NT$1.72 (up from NT$0.74 in 2Q 2021). Revenue: NT$209.1m (down 3.3% from 2Q 2021). Net income: NT$68.8m (up 209% from 2Q 2021). Profit margin: 33% (up from 10% in 2Q 2021). The increase in margin was driven by lower expenses. Revenue exceeded analyst estimates by 5.6%. Earnings per share (EPS) also surpassed analyst estimates by 192%. Over the next year, revenue is forecast to grow 32%, compared to a 39% growth forecast for the industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.
お知らせ • Aug 03SYN-TECH Chem. & Pharm. Co., Ltd. Announces Executive ChangesSYN-TECH Chem. & Pharm. Co., Ltd. announced that Chun-Cheng, Hung/synthesis department manager of SCP, has replaced Chun-Tzer, Tsai/director of Syn-Tech, as Research and development officer. Syn-Tech has announced the change of research and development officer on July 1, 2022. The case was approved by the board of Syn-Tech on August 1, 2022.
Upcoming Dividend • Jul 14Upcoming dividend of NT$1.93 per shareEligible shareholders must have bought the stock before 21 July 2022. Payment date: 19 August 2022. Payout ratio is a comfortable 75% but the company is paying out more than the cash it is generating. Trailing yield: 3.0%. Lower than top quartile of Taiwanese dividend payers (6.8%). In line with average of industry peers (2.8%).
お知らせ • Jul 03SYN-TECH Chem. & Pharm. Co., Ltd. Announces Change of Research and Development OfficerSYN-TECH Chem. & Pharm. Co., Ltd. announced change of research and development officer. Name, title, and resume of the previous position holder: Chun-Tzer, Tsai/director of Syn-Tech. Name, title, and resume of the new position holder: Chun-Cheng, Hung/synthesis department manager of SCP. Effective date is July 1, 2022.
お知らせ • Jun 22SYN-TECH Chem. & Pharm. Co., Ltd. Announces Cash Dividend, Payable on August 19, 2022SYN-TECH Chem. & Pharm. Co., Ltd. announced cash dividend of TWD 86,128,033 (TWD 2.15 per share). Ex-rights (Ex-dividend) date is July 21, 2022. Ex-rights (Ex-dividend) record date is July 27, 2022. Payment date of cash dividend distribution is August 19, 2022.
Reported Earnings • May 10First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: EPS: NT$0.85 (down from NT$1.73 in 1Q 2021). Revenue: NT$159.5m (down 32% from 1Q 2021). Net income: NT$34.2m (down 34% from 1Q 2021). Profit margin: 22% (in line with 1Q 2021). Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) also surpassed analyst estimates by 73%. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
Price Target Changed • Apr 27Price target decreased to NT$66.00Down from NT$100.00, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of NT$65.30. Stock is down 35% over the past year. The company is forecast to post earnings per share of NT$2.47 for next year compared to NT$3.38 last year.
Reported Earnings • Mar 12Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: EPS: NT$3.38 (down from NT$6.21 in FY 2020). Revenue: NT$746.6m (down 24% from FY 2020). Net income: NT$103.8m (down 44% from FY 2020). Profit margin: 14% (down from 19% in FY 2020). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 19%. Over the next year, revenue is expected to shrink by 9.3% compared to a 20% growth forecast for the pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 5% per year.
Reported Earnings • Nov 10Third quarter 2021 earnings released: EPS NT$0.94 (vs NT$1.14 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and revenues, although profit margins were improved. Third quarter 2021 results: Revenue: NT$159.2m (down 28% from 3Q 2020). Net income: NT$28.2m (down 18% from 3Q 2020). Profit margin: 18% (up from 16% in 3Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Sep 09Upcoming dividend of NT$4.00 per shareEligible shareholders must have bought the stock before 16 September 2021. Payment date: 07 October 2021. Trailing yield: 5.5%. Within top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (2.3%).
Reported Earnings • Aug 06Second quarter 2021 earnings released: EPS NT$0.74 (vs NT$2.35 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: NT$216.3m (down 29% from 2Q 2020). Net income: NT$22.2m (down 69% from 2Q 2020). Profit margin: 10% (down from 23% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
Reported Earnings • May 06First quarter 2021 earnings released: EPS NT$1.73 (vs NT$1.56 in 1Q 2020)The company reported a solid first quarter result with improved earnings and profit margins, although revenues were flat. First quarter 2021 results: Revenue: NT$235.6m (flat on 1Q 2020). Net income: NT$52.0m (up 11% from 1Q 2020). Profit margin: 22% (up from 20% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Apr 25Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to NT$95.60, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 17x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 35% over the past three years.
分析記事 • Mar 19SYN-TECH Chem. & Pharm (GTSM:1777) Could Easily Take On More DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Mar 18SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777) agreed to acquire API synthesis department of Standard Chemical from Standard Chem & Pharm CO., LTD. (TSEC:1720) for TWD 341 million.SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777) agreed to acquire API synthesis department of Standard Chemical from Standard Chem & Pharm CO., LTD. (TSEC:1720) for TWD 341 million on March 16, 2021. The transaction will be settled by exchange of 4.5 million shares of SYN-TECH of NTD 75.24 per share. If there is insufficient exchange for one share, SYN-TECH shall, within 30 days after completing amendment registration, pay the difference between assessed business value and the share value in cash to SCP at once. The deal is subject to Standard Chemical obtaining approval from shareholders and is expected to close on October 1, 2021.
Reported Earnings • Mar 18Full year 2020 earnings released: EPS NT$6.21 (vs NT$5.31 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$983.8m (up 3.9% from FY 2019). Net income: NT$186.7m (up 17% from FY 2019). Profit margin: 19% (up from 17% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 17SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, Jun 18, 2021SYN-TECH Chem. & Pharm. Co., Ltd., Annual General Meeting, Jun 18, 2021, at 14:00 Taipei Standard Time. Location: No.168, Kai Yuan Rd., Hsin-Ying District, Tainan City Taiwan Agenda: To consider 2020 Business Report; to consider Supervisors' Review Report on 2020 Financial Statements; to consider 2020 Employees' Compensation and Directors & Supervisors' Compensation Information; to consider Syn-Tech will transfer the API synthesis department that spinning-off from S.C.P, and issue new shares; to consider 2020 Business Report and Financial Statements; to consider the proposed distribution plan for year 2020 earnings; to consider the amendment to the Articles of Incorporation; to consider the amendment to the Procedures for Election of Directors and Supervisors; to consider the amendment to the Regulations Governing the Acquisition and Disposal of Assets; to consider the amendment to the Regulations Governing Loaning of Funds; and to consider other matters.
Is New 90 Day High Low • Feb 27New 90-day high: NT$82.50The company is up 9.0% from its price of NT$75.70 on 27 November 2020. The Taiwanese market is up 15% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 5.0% over the same period.
分析記事 • Feb 26Here's What You Should Know About SYN-TECH Chem. & Pharm. Co., Ltd.'s (GTSM:1777) 4.6% Dividend YieldIs SYN-TECH Chem. & Pharm. Co., Ltd. ( GTSM:1777 ) a good dividend stock? How can we tell? Dividend paying companies...
分析記事 • Feb 05Declining Stock and Decent Financials: Is The Market Wrong About SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777)?SYN-TECH Chem. & Pharm (GTSM:1777) has had a rough month with its share price down 1.2%. However, stock prices are...
分析記事 • Jan 10SYN-TECH Chem. & Pharm's (GTSM:1777) Shareholders Are Down 11% On Their SharesIdeally, your overall portfolio should beat the market average. But every investor is virtually certain to have both...
Is New 90 Day High Low • Dec 21New 90-day high: NT$77.30The company is up 2.0% from its price of NT$75.50 on 23 September 2020. The Taiwanese market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 13% over the same period.
分析記事 • Dec 19SYN-TECH Chem. & Pharm (GTSM:1777) Seems To Use Debt Rather SparinglySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Nov 28Here's What You Should Know About SYN-TECH Chem. & Pharm. Co., Ltd.'s (GTSM:1777) 4.6% Dividend YieldIs SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777) a good dividend stock? How can we tell? Dividend paying companies...
Reported Earnings • Nov 05Third quarter 2020 earnings released: EPS NT$1.14The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$220.3m (down 20% from 3Q 2019). Net income: NT$34.3m (down 39% from 3Q 2019). Profit margin: 16% (down from 21% in 3Q 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Oct 13New 90-day low: NT$73.70The company is down 16% from its price of NT$88.00 on 15 July 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 11% over the same period.
Is New 90 Day High Low • Sep 22New 90-day low: NT$75.60The company is down 16% from its price of NT$89.50 on 24 June 2020. The Taiwanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period.
